Ixekizumab superior to Guselkumab in people with moderate to severe plaque psoriasis
Data were presented at the 5th Annual Maui Derm NP+PA Fall meeting from the phase 4 IXORA-R study, the first head-to-head ( H2H ) study between an IL-17A inhibitor and an IL-23/p19 inhibitor using the ...
read article